274 related articles for article (PubMed ID: 33295110)
1. Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients.
Fukuda N; Yunokawa M; Fujiwara Y; Wang X; Ohmoto A; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1322. PubMed ID: 33295110
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
[TBL] [Abstract][Full Text] [Related]
3. Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial.
Guigay J; Le Caer H; Ferrand FR; Geoffrois L; Saada-Bouzid E; Fayette J; Sire C; Cupissol D; Blot E; Guillet P; Pavillet J; Bozec L; Capitain O; Rolland F; Debourdeau P; Pointreau Y; Falandry C; Lopez S; Coutte A; Chatellier T; Dalloz P; Ortholan C; Michel C; Lacas B; Cheurfa N; Schwob D; Bourhis J; Mertens C; Aupérin A;
Lancet Healthy Longev; 2024 Jun; 5(6):e392-e405. PubMed ID: 38759667
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Sato H; Tsukahara K; Okamoto I; Katsube Y; Shimizu A; Kondo T; Hanyu K; Fushimi C; Okada T; Miura K
Acta Otolaryngol; 2019 Feb; 139(2):201-205. PubMed ID: 30794080
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
Guo Y; Luo Y; Zhang Q; Huang X; Li Z; Shen L; Feng J; Sun Y; Yang K; Ge M; Zhu X; Wang L; Liu Y; He X; Bai C; Xue K; Zeng Y; Chang X; Chen W; Lin T
Eur J Cancer; 2021 Oct; 156():35-45. PubMed ID: 34418665
[TBL] [Abstract][Full Text] [Related]
6. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?
Mutlu H; Salim DK; Gündüz Ş; Eryılmaz MK; Musri FY; Coşkun HŞ
J Cancer Res Ther; 2017; 13(3):510-513. PubMed ID: 28862218
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Soulières D; Aguilar JL; Chen E; Misiukiewicz K; Ernst S; Lee HJ; Bryant K; He S; Obasaju CK; Chang SC; Chin S; Adkins D
BMC Cancer; 2016 Jan; 16():19. PubMed ID: 26768732
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Chevalier T; Daste A; Saada-Bouzid E; Loundou A; Peyraud F; Lambert T; Le Tourneau C; Peyrade F; Dupuis C; Alfonsi M; Fayette J; Reure J; Huguet F; Fakhry N; Toullec C; Salas S
Cancer Med; 2021 Jun; 10(12):3952-3963. PubMed ID: 34080776
[TBL] [Abstract][Full Text] [Related]
10. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
[TBL] [Abstract][Full Text] [Related]
11. Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial.
Guo Y; Shi M; Yang A; Feng J; Zhu X; Choi YJ; Hu G; Pan J; Hu C; Luo R; Zhang Y; Zhou L; Cheng Y; Lüpfert C; Cai J; Shi Y
Head Neck; 2015 Aug; 37(8):1081-7. PubMed ID: 24710768
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
Keam B; Lee KW; Lee SH; Kim JS; Kim JH; Wu HG; Eom KY; Kim S; Ahn SH; Chung EJ; Kwon SK; Jeong WJ; Jung YH; Kim JW; Heo DS
Oncologist; 2019 Jun; 24(6):751-e231. PubMed ID: 30796155
[TBL] [Abstract][Full Text] [Related]
13. Platinum rechallenge in recurrent head and neck squamous cell carcinoma after primary chemoradiation.
Rambeau A; Licaj I; Gery B; Gervais R; Florescu C; Babin E; De Raucourt D; Johnson A; Thariat J
Eur Ann Otorhinolaryngol Head Neck Dis; 2019 Sep; 136(4):257-261. PubMed ID: 31003864
[TBL] [Abstract][Full Text] [Related]
14. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
Grünwald V; Chirovsky D; Cheung WY; Bertolini F; Ahn MJ; Yang MH; Castro G; Berrocal A; Sjoquist K; Kuyas H; Auclair V; Guillaume X; Joo S; Shah R; Harrington K;
Oral Oncol; 2020 Mar; 102():104526. PubMed ID: 31978755
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
Gulati S; Desai J; Palackdharry SM; Morris JC; Zhu Z; Jandarov R; Riaz MK; Takiar V; Mierzwa M; Gutkind JS; Molinolo A; Desai PB; Sadraei NH; Wise-Draper TM
Cancer; 2020 Jan; 126(2):354-362. PubMed ID: 31626727
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial.
Zheng Y; Dou H; Li Q; Sun Y; Wang Y; Zhang W
Cancer Control; 2021; 28():1073274821997444. PubMed ID: 34029149
[TBL] [Abstract][Full Text] [Related]
17. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey.
Burgy M; Barthélémy P; Lefevre F; Dupret-Bories A; Truntzer P; Korenbaum C; Flesch H; Bronner G; Borel C
Oncology; 2017; 93(1):11-17. PubMed ID: 28423384
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Kim MJ; Kim SM; Jung HA; Hong JY; Chang WJ; Choi MK; Kim HS; Sun JM; Park K; Ahn MJ
Korean J Intern Med; 2019 Sep; 34(5):1107-1115. PubMed ID: 29914230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
